信托逾期 高管更迭 振东制药连年亏损暴露内控之弊

Core Viewpoint - Shanxi Zhendong Pharmaceutical Co., Ltd. expects a net profit loss of 220 million to 280 million yuan for 2025, a reduction from the previous year's loss of 1.32 billion yuan, indicating ongoing challenges despite a narrowing loss margin [1] Group 1: Financial Performance - The company has experienced continuous revenue decline, with revenues of 3.729 billion yuan in 2022, 3.626 billion yuan in 2023, and 2.971 billion yuan in 2024 [2] - Cumulative net losses have exceeded 1.4 billion yuan over the past years, with the company actively engaging in aggressive investment strategies, including 1.44 billion yuan in entrusted financial management as of mid-2025 [2] - The company faces a risk of 200 million yuan in trust financial management principal and interest not being fully repaid [2][3] Group 2: Business Operations and Challenges - The company’s main business includes generic and innovative drugs in oncology, dermatology, and digestive fields, as well as traditional Chinese medicine [2] - The decline in sales and prices of certain products due to industry policy and market environment changes has contributed to the expected losses for 2025 [2] - The company has been involved in significant legal and financial disputes, including a 5 billion yuan arbitration payment to Longdi Pharmaceutical due to product quality issues [5] Group 3: Management and Governance Issues - Frequent changes in key personnel have been noted, including the resignation of the former chairman due to regulatory penalties [6] - The company has faced public reprimands and penalties for financial misconduct, including the improper transfer of funds to its parent company, Zhendong Group [7] - The company has received multiple inquiries from the Shenzhen Stock Exchange regarding its annual reports over the past five years, indicating ongoing scrutiny [8]